Sofia Holmqvist-Jämsén, PhD, from the University of Helsinki

Are Allergies Hurting Your Patients' Voice? Study Shows It Might

A recent study identified a link between respiratory allergies and frequent vocal symptoms, particularly among women. The population-based study of 1220 Finnish adults, led by Sofia Holmqvist-Jämsén, PhD, from the University of Helsinki, examined diagnosed 

 and their relationship to 6 self-reported vocal symptoms: hoarseness, strained or tired voice, voice breaks, difficulty being heard, throat clearing or coughing, and sensation of a lump in the throat.

Overall, 25.6% of participants reported a diagnosed respiratory allergy, with women slightly more affected than men (26.4% vs 24.1%). Across the sample, 19.8% reported ≥2 vocal symptoms occurring weekly or daily in the past year.

The most frequently reported symptom was coughing or throat clearing while talking (25.9%), followed by sensation of tension or a lump in the throat (14.3%), hoarse or low voice (12.5%), and strained or tired voice (11.3%). Less commonly reported symptoms were difficulty being heard (9.5%) and voice breaks (7.7%).

Women consistently reported greater rates of frequent symptoms compared with men: strained/tired voice (14.7% vs 4.6%), hoarse/low voice (15.6% vs 6.4%), lump in the throat (16.4% vs 10.1%), and voice breaks (9.4% vs 4.4%). Respiratory allergies were associated with a greater burden in females (P <.01%) but not in men.

, Holmqvist-Jämsén recommended clinicians ask targeted questions to assess vocal complaints in patients with allergies, such as “Do you get hoarse or lose vocal function or flexibility during allergy seasons? Do you feel that your voice gets tired or strained during the day? Do you need to clear your throat while speaking?” She emphasized particular attention for high voice-use professions such as teachers, singers, coaches, healthcare workers, and clergy, suggesting seasonal planning, preventive voice strategies, and lower thresholds for referral to voice specialists.

The study highlights the need for prospective and interventional research using objective voice measures, laryngoscopy, and biomarker assessment to clarify mechanisms.

“Ask about voice when managing allergy and consider allergy when evaluating voice,” Holmqvist-Jämsén said. “This kind of coordinated care might prevent a cycle of cough and throat clearing and phonotrauma that prolongs recovery.”

Part 1 of the interview with Holmqvist-Jämsén can be viewed 

Holmqvist-Jämsén has no reported disclosures.

Holmqvist-Jämsén S, Wakene H, Jern P, Simberg S. Association Between Respiratory Allergies and Vocal Symptoms: A Cross-sectional Population-Based Study. 

Videos

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Respiratory Allergies Linked to Frequent Vocal Symptoms, With Sofia Holmqvist-Jämsén, PhD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has approved label expansions for a pair of 

 transmembrane conductance regulator (CFTR) modulator regimens, vanzacaftor/tezacaftor/ivacaftor (ALYFTREK) and elexacaftor/tezacaftor/ivacaftor (TRIKAFTA), broadening eligibility to an estimated 95% of people with CF in the United States, according to an announcement from Vertex Pharmaceuticals on April 1, 2026.¹ 

The expanded indications now encompass any 

 gene variant resulting in production of CFTR protein, in addition to variants previously identified as clinically or 

 responsive. Vanzacaftor/tezacaftor/ivacaftor is now indicated for patients aged 6 years and older, while elexacaftor/tezacaftor/ivacaftor’s indication extends to patients aged 2 years and older.¹ The breadth of the new labeling language marks a shift from variant-specific enumeration toward a functional, mechanism-based eligibility criterion.

“This groundbreaking approval represents more than 20 years of innovation in CF, including testing over 600 variants in our laboratory, demonstrating clinical effects in large clinical trials, and studying younger people with CF so they can be treated as early as possible,” said Carmen Bozic, MD, executive vice president of Global Medicines Development and Medical Affairs and chief medical officer at Vertex. 

The label expansions were supported by clinical and/or 

 variants for vanzacaftor/tezacaftor/ivacaftor and 521 variants for elexacaftor/tezacaftor/ivacaftor, according to the company's announcement. The regulatory filing was backed by an accumulated dataset incorporating laboratory assay data and clinical evidence generated across multiple studies. 

CF Disease Burden and Treatment Landscape

CF is an autosomal recessive disease caused by pathogenic variants in the 

 gene, affecting more than 97,000 people across the US, Europe, Australia, and Canada.¹ The disease causes progressive multiorgan dysfunction with a median age of death historically reported in the fourth decade of life.¹ Prior to the development of CFTR modulators, treatment was directed at managing downstream consequences of dysfunctional chloride transport rather than the underlying molecular defect.

CFTR modulators represent a class of small molecules that potentiate or correct aberrant CFTR protein function. Ivacaftor (a CFTR potentiator) was the first approved agent in this class and subsequent combination regimens incorporating correctors, such as tezacaftor, elexacaftor, vanzacaftor, expanded eligible populations by addressing the more common 

Elexacaftor/tezacaftor/ivacaftor received initial FDA approval in 2019 and has since undergone multiple label expansions down to younger age groups. Vanzacaftor/tezacaftor/ivacaftor, a next-generation triple combination incorporating vanzacaftor and deutivacaftor, represents a more recent addition to the approved regimen portfolio.

Vanzacaftor/tezacaftor/ivacaftor combines vanzacaftor and tezacaftor (CFTR correctors that facilitate proper protein folding and trafficking to the cell surface) with ivacaftor (a CFTR potentiator that increases channel open probability). Elexacaftor/tezacaftor/ivacaftor similarly combines elexacaftor and tezacaftor as a dual-corrector backbone with ivacaftor as the potentiator. 

The expanded labeling reflects evidence these mechanisms may confer benefit across a broader range of protein-producing variants, regardless of the specific location of the variant within the CFTR protein, according to the announcement.¹

“With this label expansion, any variant that results in production of CFTR protein is now included in the ALYFTREK and TRIKAFTA labels, validating that these medicines can restore CFTR function and provide clinical benefit to patients regardless of where in the CFTR protein a variant is located,” Bozic added.

Safety Profile and Monitoring Requirements

Both agents carry boxed warnings for drug-induced liver injury (DILI). Postmarketing reports have associated elexacaftor/tezacaftor/ivacaftor with cases of liver failure leading to transplantation and death in patients with and without preexisting liver disease; hepatic injury has been reported as early as 1 month after initiation and as late as 15 months. For vanzacaftor/tezacaftor/ivacaftor, transaminase elevations have been observed, though the prescribing information does not yet carry reports of fatal hepatic outcomes specific to that agent.¹

Current labeling recommends liver function testing prior to initiation, monthly for the first 6 months, every 3 months through month 18, and at least annually thereafter. Both agents are contraindicated in severe hepatic impairment and are not recommended in moderate hepatic impairment.¹

Additional postmarketing safety signals include hypersensitivity reactions, intracranial hypertension, neuropsychiatric events, and non-congenital lens opacities in pediatric patients. Strong or moderate CYP3A inducers are not recommended for coadministration and dose reduction is required with moderate or strong CYP3A inhibitors.¹

Vertex Pharmaceuticals Incorporated. Vertex announces US FDA approval for label extensions of ALYFTREK® and TRIKAFTA®, expanding availability of these medicines to ~95% of all people with CF in the United States. BusinessWire. April 1, 2026. Accessed April 1, 2026. 

https://www.businesswire.com/news/home/20260401690804/en/Vertex-Announces-US-FDA-Approval-for-Label-Extensions-of-ALYFTREK-and-TRIKAFTA-Expanding-Availability-of-These-Medicines-to-95-of-All-People-With-CF-in-the-United-States

Vertex Pharmaceuticals. FDA Approves TRIKAFTA

 (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation | Vertex Pharmaceuticals. Vertex Pharmaceuticals. Published October 21, 2019. Accessed April 1, 2026. 

https://investors.vrtx.com/news-releases/news-release-details/fda-approves-trikafta-elexacaftortezacaftorivacaftor-and

Vertex Pharmaceuticals. Vertex Announces US FDA Approval of ALYFTREK

, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis | Vertex Pharmaceuticals. Vertex Pharmaceuticals. Published December 20, 2024. Accessed April 1, 2026. 

https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-alyftrektm-once-daily-next

Articles

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

FDA News

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

Oral Iron — Formulation Selection, Dosing Frequency, and Absorption Optimization

An expert reviews the evidence on oral iron formulation choice, the impact of dosing frequency on tolerability and absorption, and practical steps clinicians can recommend to patients to maximize oral iron uptake.

No single oral iron formulation has demonstrated clear advantages over others in terms of efficacy or tolerability, though ferrous sulfate remains the least expensive option and is a practical first choice for most patients. Gastrointestinal side effects are common with oral iron therapy, with up to 10% of patients experiencing constipation, diarrhea, or nausea — a frequency that meaningfully affects adherence and is an important consideration when counseling patients at the time of initiation. Formulation selection in practice is therefore often guided as much by cost and side effect profile as by any differential evidence of superiority among available products.

Dosing frequency is an area where the evidence has meaningfully clarified practice in recent years. Oral iron should be given at most once daily — more frequent dosing does not improve outcomes and increases the risk of side effects. The mechanism underlying this recommendation involves hepcidin: oral iron ingestion raises endogenous hepcidin levels, which can remain elevated for up to 48 hours and suppress intestinal iron absorption during that window. Every-other-day dosing exploits this biology, improving tolerability while maintaining absorption rates comparable to daily dosing. The data supporting alternate-day dosing are promising, and further studies are underway to better define its role across patient populations.

In this segment of the video discussion on IDA management, Richard Godby, MD, addresses the practical questions clinicians most commonly face when initiating oral iron therapy. He notes that while the evidence for vitamin C supplementation as an absorption enhancer — through its role in preventing insoluble iron compound formation and reducing ferric to ferrous iron— is mixed, the evidence against tea and coffee is clear and consistent: both are potent inhibitors of iron absorption and should be avoided within 1 hour of taking an oral iron supplement. Godby advises that oral iron is best absorbed on an empty stomach but can be taken with food when gastrointestinal intolerance is limiting adherence, framing tolerability as a practical priority since a regimen the patient can sustain is more valuable than an optimal one they cannot.

Learn smarter oral iron dosing: once daily or every other day to cut GI side effects, boost absorption, and avoid tea/coffee.

Video Series

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Stephen Greene, MD, is an associate professor of medicine at Duke University School of Medicine and cardiologist at the Duke Clinical Research Institute in Durham, NC. Greene is a member of HCPLive's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Expert-led podcast episode examining MRA updates at ACC 2026 Scientific Sessions

Don't Miss a Beat: MRA Updates at ACC 2026 Scientific Sessions

Few subspecialties in cardiovascular medicine have welcomed the same abundance of new data and clinical trials as heart failure specialists, particularly as it relates to 

 with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF).

Against that backdrop, the mineralocorticoid receptor antagonist (MRA) class has emerged as a focal point of ongoing debate. Current US heart failure guidelines assign MRAs a Class IIb recommendation in HFpEF, which is a designation reflecting uncertainty shaped in large part by the contested TOPCAT trial, where a post-hoc analysis of the Americas subpopulation suggested benefit, even as the full trial failed its primary endpoint.

American College of Cardiology's Annual Scientific Session (ACC.26)

, now adds a prospective null result to that record, while finerenone continues accumulating phase 3 evidence across diabetic and non-diabetic chronic kidney disease populations — most recently through the FINE-ONE and FIND-CKD trials announced ahead of ACC.26.

hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, and Stephen Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, break down the latest updates and news related to mineralocorticoid receptor agonists, including a deep dive into SPIRIT-HF and topline announcements from finerenone’s phase 3 clinical trial program.

On March 29, 2026, investigators presented results from the SPIRIT-HF trial at ACC.26 showing spironolactone did not significantly reduce the composite of heart failure hospitalization and cardiovascular death compared with placebo in patients with HFpEF or HFmrEF. 

Based on the randomized, placebo-controlled trial of 730 patients across 56 European centers, event rates at 24 months were 12.7 versus 10.8 per 100 patient-years in the spironolactone and placebo groups, respectively, with no significant difference observed across prespecified subgroups.

Secondary endpoints revealed significantly greater rates of total hospitalizations, hypotension, renal events, and hyperkalemia in the spironolactone arm, and more than half of participants assigned to the drug discontinued treatment before trial completion, largely attributable to COVID-19 pandemic disruptions. 

A pooled meta-analysis incorporating TOPCAT Americas data similarly showed no significant benefit, leaving the role of aldosterone blockade in HFpEF and HFmrEF unresolved pending additional registry data.

On November 6, 2025, Bayer announced positive phase 3 results from the FINE-ONE trial evaluating finerenone in adults with type 1 diabetes and chronic kidney disease. Based on the randomized, double-blind, placebo-controlled trial in 242 participants, finerenone added to standard of care demonstrated a 25% relative reduction in urine albumin-to-creatinine ratio from baseline over 6 months compared with placebo (95% CI, 0.65–0.87; 

On March 16, 2026, Bayer announced positive phase 3 results from the FIND-CKD trial evaluating finerenone versus placebo added to standard of care in adults with non-diabetic chronic kidney disease. Based on the randomized phase 3 trial, finerenone demonstrated a statistically significant improvement in eGFR slope, the mean annual rate of eGFR change from baseline to month 32, a validated surrogate endpoint for kidney failure risk.

Finerenone has now shown kidney-protective benefits across 5 completed phase 3 studies spanning diabetic and non-diabetic CKD populations. In their March 16 announcement, Bayer disclosed plans to submit the FIND-CKD data to health authorities to pursue a label extension to non-diabetic CKD.

Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.

American College of Cardiology. Study Finds No Significant Benefit of Spironolactone in HFpEF or HFmrEF - American College of Cardiology. American College of Cardiology. Published March 29, 2026. Accessed March 31, 2026. 

https://www.acc.org/About-ACC/Press-Releases/2026/03/29/14/57/Study-Finds-No-Significant-Benefit-of-Spironolactone-in-HFpEF-or-HFmrEF

Bayer. Finerenone showed statistically significant reduction of UACR in adults with chronic kidney disease associated with type 1 diabetes. Bayer. Published November 6, 2025. Accessed November 6, 2025. 

https://www.bayer.com/media/en-us/finerenone-showed-statistically-significant-reduction-of-uacr-in-adults-with-chronic-kidney-disease-associated-with-type-1-diabetes/

Bayer. KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease. Bayer.com. Published March 16, 2026. Accessed March 31, 2026. 

https://www.bayer.com/en/us/news-stories/kerendiar-meets-primary-endpoint

Podcasts

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chronic Kidney Disease

Type 2 Diabetes

Type 1 Diabetes

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Don’t Miss a Beat

The Don't Miss a Beat Podcast is a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Professor and Chair of the Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases and in the Peter O'Donnell Jr. School of Public Health at UT Southwestern Medical Center in Dallas

Evolving Research Landscape Drives Progress in CLE at AAD 2026

Cutaneous lupus erythematosus (CLE) is a disease whose therapeutic stagnation has stood in stark contrast to the scientific progress made in understanding its underlying biology. Over the past two decades, advances in immunology have illuminated the central role of plasmacytoid dendritic cells, type I interferon signaling, and innate immune dysregulation in driving the skin inflammation, tissue injury, and scarring that define the disease.¹ That growing mechanistic clarity has not only reframed how clinicians think about CLE pathophysiology but has begun to translate into a new generation of rationally designed therapeutic candidates targeting the specific immunological pathways responsible for disease activity.

Litifilimab is perhaps the clearest example of that translation. Its development as a BDCA2-targeting monoclonal antibody was predicated on the understanding that pDC-driven type I interferon production is a proximal driver of lupus pathogenesis, and its two positive Phase 2 trials in CLE represent the most advanced clinical validation of that mechanistic hypothesis to date.² The progress made in CLE is also inseparable from broader advances in lupus research, where a deepening understanding of immune dysregulation across the spectrum of disease has created shared scientific infrastructure that benefits both systemic and cutaneous manifestations.

For patients who have lived with inadequate treatment options for generations, the convergence of scientific understanding and clinical evidence now underway represents a genuine inflection point. In this final segment, Joseph Merola, MD, MMSc, and Victoria Werth, MD, reflect on how the field's evolving understanding of CLE pathophysiology has shaped the current moment in drug development, and what the trajectory of innovation suggests for the future of care in this long-underserved disease.

Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. 

 2019;129(3):1359-1371. doi:10.1172/JCI124466

Biogen Inc. Biogen announces second positive Phase 2 litifilimab trial in cutaneous lupus erythematosus at 2026 American Academy of Dermatology Annual Meeting, showing a significant reduction in skin disease activity. Published March 28, 2026. 

https://investors.biogen.com/news-releases/news-release-details/biogen-announces-second-positive-phase-2-litifilimab-trial

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.

AMETHYST Phase 3 and Remaining Questions Surrounding Litifilimab in CLE

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Potential of Targeting BDCA2 in Cutaneous Lupus Erythematosus Management

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Navigating Multidisciplinary Care for CLE in an Evolving Landscape

Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.

Understanding AMETHYST Design and Patient Needs in CLE

With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.

Understanding Unmet Need and Recent Advances in CLE at AAD 2026 

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Together-PsA: Ixekizumab + Tirzepatide Deliver Superior Efficacy Over Biologic Monotherapy, With Joseph Merola, MD

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

ONWARD: Oral Envudeucitinib Demonstrates High PASI Responses in Phase 3, With Andrew Blauvelt, MD

Cheng Zhou, MD, is a professor and chair of the department of dermatology at Peking University People`s Hospital in China.

Phase 3 data on rademikibart in moderate-to-severe atopic dermatitis (AD) have been released from the AAD late-Breaking research session.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

RADIANT-AD: Rademikibart Effective Over 52 Weeks in Atopic Dermatitis, With Cheng Zhou, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

REMIX: Early CSU Symptom Improvement Observed with Remibrutinib Therapy

Monica Kraft, MD, is Murray M. Rosenberg Professor of Medicine and System Chair for the Department of Medicine at Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai.

Deep learning applied to routine ECGs identifies subtle cardiac signals linked to early COPD, potentially enabling earlier diagnosis and intervention.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Latest News

Respiratory Allergies Linked to Frequent Vocal Symptoms, With Sofia Holmqvist-Jämsén, PhD

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

Oral Iron — Formulation Selection, Dosing Frequency, and Absorption Optimization

Don't Miss a Beat: MRA Updates at ACC 2026 Scientific Sessions

Evolving Research Landscape Drives Progress in CLE at AAD 2026